GB2140687B - Osmotic drug delivery system - Google Patents

Osmotic drug delivery system

Info

Publication number
GB2140687B
GB2140687B GB08334189A GB8334189A GB2140687B GB 2140687 B GB2140687 B GB 2140687B GB 08334189 A GB08334189 A GB 08334189A GB 8334189 A GB8334189 A GB 8334189A GB 2140687 B GB2140687 B GB 2140687B
Authority
GB
United Kingdom
Prior art keywords
delivery system
drug delivery
osmotic drug
osmotic
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB08334189A
Other versions
GB8334189D0 (en
GB2140687A (en
Inventor
Patrick S L Wong
Brian Barclay
Joseph C Deters
Felix Theeuwes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23961585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2140687(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of GB8334189D0 publication Critical patent/GB8334189D0/en
Publication of GB2140687A publication Critical patent/GB2140687A/en
Application granted granted Critical
Publication of GB2140687B publication Critical patent/GB2140687B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
GB08334189A 1983-05-11 1983-12-22 Osmotic drug delivery system Expired GB2140687B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49376083A 1983-05-11 1983-05-11

Publications (3)

Publication Number Publication Date
GB8334189D0 GB8334189D0 (en) 1984-02-01
GB2140687A GB2140687A (en) 1984-12-05
GB2140687B true GB2140687B (en) 1987-03-18

Family

ID=23961585

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08334189A Expired GB2140687B (en) 1983-05-11 1983-12-22 Osmotic drug delivery system

Country Status (20)

Country Link
JP (1) JPS6041609A (en)
AT (1) AT397180B (en)
AU (1) AU566110B2 (en)
BE (1) BE898819A (en)
CA (1) CA1222950A (en)
CH (1) CH669329A5 (en)
DE (1) DE3417113A1 (en)
DK (1) DK163910C (en)
ES (1) ES8503503A1 (en)
FR (1) FR2545721B1 (en)
GB (1) GB2140687B (en)
IE (1) IE56515B1 (en)
IL (1) IL71727A (en)
IT (1) IT1178911B (en)
MX (1) MX163518B (en)
NL (1) NL192250C (en)
NO (1) NO170834C (en)
NZ (1) NZ206600A (en)
SE (1) SE455918B (en)
ZA (1) ZA842422B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993432B2 (en) 2008-11-27 2018-06-12 Bayer Intellectual Property Gmbh Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin II antagonist and/or a diuretic

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH075457B2 (en) * 1983-08-16 1995-01-25 ザ ウエルカム フアウンデ−シヨン リミテツド Pharmaceutical composition allowing the release of the active ingredient in a controlled manner
US4600773A (en) * 1983-12-01 1986-07-15 Eli Lilly And Company Crystalline cephalexin hydrochloride monohydrate
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
ES8800043A1 (en) * 1985-08-16 1987-10-16 Alza Corp Osmotic dispenser
US4963141A (en) * 1985-08-16 1990-10-16 Alza Corporation Dispensing system for administering beneficial agent formulation to ruminants
US4704118A (en) * 1985-08-16 1987-11-03 Alza Corporation Ruminant dispensing device with thermo-activated memory
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4716496A (en) * 1986-05-09 1987-12-29 Eaton Corporation Panel-mounted control station housing
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
ATE76292T1 (en) * 1987-11-25 1992-06-15 American Cyanamid Co SYSTEM FOR THE DELAYED (CONTROLLED) RELEASE OF SUBSTITUTED DIHYDROPYRIDINCALCIUM ANTAGONISTS.
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
US4855141A (en) * 1988-03-25 1989-08-08 Alza Corporation Device comprising means for protecting and dispensing fluid sensitive medicament
US4859470A (en) * 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
GR1000270B (en) * 1988-09-30 1992-05-12 Alza Corp Dose for cardiovascular troubles therapy
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
EP0408496A3 (en) * 1989-07-12 1992-07-01 Ciba-Geigy Ag Solid dosage form for pharmaceutical substances
US5000962A (en) * 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
US5067960A (en) * 1989-12-06 1991-11-26 Medtronic, Inc. Muscle fitness detection by colorimetry
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5081161A (en) * 1990-06-15 1992-01-14 E. I. Du Pont De Nemours And Company Process for making shaped articles of a thermoplastic resin having a microcellular structure
NZ238867A (en) * 1990-07-12 1993-08-26 Alza Corp Dosage form for delayed release comprising pharmaceutically active substance and a drug-release hindering means and a second composition which imbibes fluid, expands, and ejects the active substance from the device
JPH0794379B2 (en) * 1990-08-07 1995-10-11 ファイザー・インコーポレーテッド Methods of using interfacial polymerized membranes in release formulations
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
WO1992005775A1 (en) * 1990-09-28 1992-04-16 Pfizer Inc. Dispensing device containing a hydrophobic medium
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
ES2158871T3 (en) * 1993-02-23 2001-09-16 Wolfgang Dr Werner USE OF A CALCIUM FORMULATION IN A MEDICINAL PRODUCT FOR THERAPEUTIC APPLICATION TO DAIRY COWS SUFFERING HYPOCALCEMIA.
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
CN101317825A (en) * 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 Controlled release hydrocodone formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
DE10129725A1 (en) 2001-06-20 2003-01-02 Bayer Ag Combination therapy of substituted oxazolidinones
DE10300111A1 (en) 2003-01-07 2004-07-15 Bayer Healthcare Ag Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide
US10226428B2 (en) 2003-09-19 2019-03-12 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
EA013106B1 (en) * 2003-09-19 2010-02-26 Сан Фарма Адвансед Ресьорч Компани Лтд. Oral drug delivery system
US10213387B2 (en) 2003-09-19 2019-02-26 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
DE10355461A1 (en) 2003-11-27 2005-06-23 Bayer Healthcare Ag Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
DE102004062475A1 (en) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Solid, orally administrable, modified release pharmaceutical dosage forms
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005031577A1 (en) 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmaceutical dosage forms containing a combination of nifedipine and / or nisoldipine and an angiotensin II antagonist
DE102005045518A1 (en) 2005-09-23 2007-03-29 Bayer Healthcare Ag New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa
RU2429236C2 (en) 2005-10-04 2011-09-20 Байер Шеринг Фарма Акциенгезельшафт Novel polymorphous form and amorphous form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide
DE102005047561A1 (en) 2005-10-04 2007-04-05 Bayer Healthcare Ag Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance
BRPI0925100A2 (en) * 2009-06-02 2016-07-19 Dow Global Technologies Llc osmotic dosage form and process for preparing an osmotic dosage form
DE102011007272A1 (en) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Branched 3-phenylpropionic acid derivatives and their use
KR20150007297A (en) 2012-05-07 2015-01-20 바이엘 파마 악티엔게젤샤프트 Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
UY34856A (en) 2012-07-03 2013-12-31 Bayer Pharma AG PHARMACEUTICAL PRESENTATION FORMS CONTAINING 5-CHLORO-N - ({(5S) -2-OXO-3- [4- (3-OXO-4- MORPHOLINYL) -PHENYL] -1,3-OXAZOLIDIN-5-IL} -METIL) -2-THIOFENCARBOXAMIDE
JP5941117B2 (en) * 2014-10-17 2016-06-29 ダウ グローバル テクノロジーズ エルエルシー Sustained release formulation
JOP20210019A1 (en) 2018-07-24 2021-01-24 Bayer Ag Pharmaceutical dosage form which can be administered orally and has modified release
JP2021531297A (en) 2018-07-24 2021-11-18 バイエル・アクチエンゲゼルシヤフト Pharmaceutical dosage form that can be administered orally and has a modified release
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL38538A (en) * 1971-01-13 1974-09-10 Alza Corp Osmotic dispenser
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993432B2 (en) 2008-11-27 2018-06-12 Bayer Intellectual Property Gmbh Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin II antagonist and/or a diuretic

Also Published As

Publication number Publication date
FR2545721A1 (en) 1984-11-16
GB8334189D0 (en) 1984-02-01
IT1178911B (en) 1987-09-16
DE3417113C2 (en) 1989-02-02
BE898819A (en) 1984-05-30
DK99784A (en) 1984-11-12
FR2545721B1 (en) 1987-11-06
ZA842422B (en) 1984-11-28
IL71727A0 (en) 1984-09-30
NO840248L (en) 1984-11-12
NL192250B (en) 1996-12-02
NL8401470A (en) 1984-12-03
CA1222950A (en) 1987-06-16
DK163910B (en) 1992-04-21
IE56515B1 (en) 1991-08-28
ATA88084A (en) 1993-07-15
NZ206600A (en) 1987-01-23
SE8402512L (en) 1984-11-12
ES532018A0 (en) 1985-03-01
AU2251183A (en) 1984-11-15
JPS6041609A (en) 1985-03-05
IL71727A (en) 1989-01-31
GB2140687A (en) 1984-12-05
IT8467283A0 (en) 1984-03-23
IT8467283A1 (en) 1985-09-23
NO170834C (en) 1992-12-16
DK163910C (en) 1992-09-14
CH669329A5 (en) 1989-03-15
NO170834B (en) 1992-09-07
AU566110B2 (en) 1987-10-08
SE455918B (en) 1988-08-22
ES8503503A1 (en) 1985-03-01
IE840010L (en) 1984-11-11
MX163518B (en) 1992-05-25
DE3417113A1 (en) 1984-11-15
SE8402512D0 (en) 1984-05-09
JPH0575725B2 (en) 1993-10-21
AT397180B (en) 1994-02-25
DK99784D0 (en) 1984-02-24
NL192250C (en) 1997-04-03

Similar Documents

Publication Publication Date Title
GB2140687B (en) Osmotic drug delivery system
GB2135880B (en) Osmotic drug delivery device
GB8322007D0 (en) Pharmaceutical delivery system
DE3369468D1 (en) Osmotic drug delivery system
GB2139093B (en) Anticoagulant delivery system
GB8519530D0 (en) Drug delivery system
GB2155787B (en) Osmotic delivery devices
EP0274467A4 (en) Hepatocyte directed vesicle delivery system.
GB2185397B (en) Drug delivery system
GB8630273D0 (en) Pharmaceutical delivery systems
ZA832333B (en) Closed drug delivery system
GB2206047B (en) Multi-layer delivery system
ZA857355B (en) Novel drug delivery system
PH24331A (en) Drug delivery system
DE3570594D1 (en) Closed drug delivery system
GB8712176D0 (en) Drug delivery system
EP0128831A3 (en) Drug administration
GB8407052D0 (en) Catalyst delivery system
EP0126684A3 (en) Drug delivery system utilizing thermosetting gels
EP0274896A3 (en) Hanky delivery system
GB2146525B (en) Drug delivery system
ZA823980B (en) 5-asa drug delivery system
EP0182502A3 (en) Drug delivery system
EP0204831A4 (en) Therapeutic agent delivery system.
EP0205342A3 (en) Agent delivery systems

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20031221